Dystrogen Therapeutics is a clinical-stage regenerative medicine company focusing on rare genetic diseases. It is engaged in the testing of dystrophin expressing chimeric (DEC) therapy for Duchenne muscular dystrophy. In addition, the company develops multi-chimeric cells for treating patients with sickle cell diseases.